Publication | Closed Access

Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment

Translational MedicineImmunologyPharmacologyAnti-pd-1/pd-l1 TreatmentTherapeutic EfficacyImmune Checkpoint InhibitorPharmacotherapyRamucirumab EnhancesMedicineNovel Therapy